ClinicalTrials.gg
CompletedNCT04891679OMSUpdated May 18, 2021

Induction of Labor by Oral Misoprostol Solution

An interventional study of Oral misoprostol solution (OMS) in Induction of Labor, sponsored by Christian Medical College and Hospital, Ludhiana, India. Completed at 1 site in India. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Christian Medical College and Hospital, Ludhiana, India · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Dec 2017, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

AIM: To evaluate effectiveness and safety of titrated oral misoprostol solution (OMS) in comparison with static-dose oral misoprostol solution for induction of labor at term.

Women with singleton live pregnancy at term without any complications who were admitted in labor room for induction of labor were enrolled.

Study involves allocation of selected women in two groups randomly and use of either titrated or static oral misoprostol dose regimen to induce labor. Possible benefits included rapid induction of labor with oral drug regimen which is easier to comply as compared to vaginal regimens. Women were at risk of all the complications associated with induction of labor like labor abnormalities, risk of cesarean section, non reassuring fetal status.

Read the detailed description

This comparative randomized study was conducted in the Department of Obstetrics and Gynecology, Christian medical college and hospital, Ludhiana for a period of one year beginning from 1st December, 2017 to 30th November, 2018. The study group comprised of all antenatal women admitted in labor room at term for induction of labor. Informed consent was taken for all selected women. Women were subjected to detailed history taking, a complete physical examination including per vaginum examination (to calculate modified bishop's score and to rule out cephalopelvic disproportion), investigations and a NST. Gestational age was established by the first date of the last menstrual period and confirmed by first trimester ultrasound. Presentation was confirmed by palpation and third trimester ultrasound.

Women after randomization were allocated into two groups. The first group (A) was induced with hourly titrated oral misoprostol regimen and the second group (B) received two hourly static oral misoprostol regimen. Once labor had started, vital signs were closely monitored every 2 hours; fetal heart rate (FHR) and uterine activity every 15 minutes during first stage of labor. Per vaginum examination was done 4-hourly or as indicated.

Primary and secondary outcome measures were noted and analyzed to compare safety and efficacy of titrated and oral misoprstol solution.

02

Conditions studied

  • Induction of Labor
03

In context

Lead sponsor

Christian Medical College and Hospital, Ludhiana, India is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singleton live pregnancy;
  2. ≥37 weeks gestation;
  3. Cephalic presentation;
  4. Reassuring fetal heart rate;
  5. Modified Bishop'score

Exclusion criteria

Exclusion Criteria:

  1. to misoprostol;
  2. Uterine scar due to previous cesarean section or other uterine surgery;
  3. Grand multipara;
  4. Multiple gestations;
  5. High risk pregnanacies • preeeclampsia with severe features • significant maternal cardiac,renal, liver disease
  6. Any to induction and vaginal delivery e.g. cephalopelvic disproportion, malpresentation, fetal compromise and ante partum hemorrhage
  7. Intrauterine fetal demise
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
264 participants (actual)

Study arms

  • Active comparator
    Group A (Titrated OMS)

    Titrated oral misoprostol solution

    Drug: Oral misoprostol solution (OMS)

  • Active comparator
    Group B (Static OMS)

    Static oral misoprostol solution

    Drug: Oral misoprostol solution (OMS)

Interventions

  • Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours. Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below. 0 hour= 20ml 1. hour= 20ml 2. hour= 30ml 3. hour= 30ml 4. hour= 30ml 5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.

06

What researchers measure

Primary outcomes

  1. Interval between induction and delivery

    The time taken from induction of labor to delivery measured as 1) \<12 hours 2) 12-24 hours 3) 24-48 hours 4) \>48 hours

    Time frame: From first dose of oral misoprostol solution (titrated/static) to childbirth; upto 5 days

Secondary outcomes

  1. Mean change in modified Bishop's score

    Measured as difference between modified bishop's score before induction of labor and at amniotomy/stopping of oral misoprostol solution regimen; minimum 0f 1 to maximum of 7.

    Time frame: From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  2. Number of misoprostol doses

    Measured as 1-2; 3-4; 5-6; 7-8; \>9

    Time frame: From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  3. Time taken to give required doses

    Measured as 1-4 hours; 5-8 hours; 9-12 hours; 13-16 hours; 17-20 hours; 21-24 hours

    Time frame: From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  4. Total misoprostol dosage

    Measured as \</=75mcg; 76-150mcg; 151-225mcg; 226-300mcg; \>301 mcg

    Time frame: From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  5. Mode of delivery

    In terms of Vaginal delivery/LSCS

    Time frame: Upto 5 days from first dose of oral misoprostol solution

  6. Indication for LSCS

    Divided into either of the following: 1. SECONDARY ARREST OF DILATATION 2. MSAF IN EARLY LABOR 3. CTG CATEGORY III 4. FAILED INDUCTION 5. CEPHALOPELVIC DISPROPORTION 6. CORD PROLAPSE 7. DEEP TRANSVERSE ARREST 8. ARREST OF DESCENT OF HEAD

    Time frame: Upto 5 days from first dose of oral misoprostol solution

  7. Oxytocin augmentation

    Required/Not required

    Time frame: From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  8. Maternal morbidity

    In terms of incidence of either of the following: 1. Incidence of tachysystole 2. Fever- intrapartum and postpartum 3. Puerperal sepsis 4. Uterine rupture

    Time frame: From first dose of oral misoprostol solution to dischage from hospital; upto 7 days

  9. Neonatal parameters

    Measured in terms of incidence of either of the following: 1. Incidence of meconium-stained liquor 2. APGAR scores at 1,5 min 3. NICU stay

    Time frame: From childbirth to discharge of the baby; upto 1 month

07

Study locations

1 site
  • Christian Medical College and Hospital
    Ludhiana, Punjab 141008, India
08

References and documents

Publications

  • Rouzi AA, Alsahly N, Alamoudi R, Almansouri N, Alsinani N, Alkafy S, Rozzah R, Abduljabbar H. Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor. Am J Obstet Gynecol. 2017 Apr;216(4):405.e1-405.e6. doi: 10.1016/j.ajog.2016.11.1054. Epub 2016 Dec 14. PubMed 27986461 ↗
  • Aduloju OP, Ipinnimo OM, Aduloju T. Oral misoprostol for induction of labor at term: a randomized controlled trial of hourly titrated and 2 hourly static oral misoprostol solution. J Matern Fetal Neonatal Med. 2021 Feb;34(4):493-499. doi: 10.1080/14767058.2019.1610378. Epub 2019 Apr 29. PubMed 31006282 ↗

Individual participant data

Plan to share: Yes — IPD that underlie the results reported in the study, after deidentification (text, tables, figures and appendices) will be shared in the excel sheet format.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available beginning immediately and ending 36 months following article publication.

Access criteria: Anyone who wishes to access the data for any purpose. Link will be made available at a later date.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Nov 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
May 18, 2021
StartActual
Dec 1, 2017
Primary completionActual
Nov 30, 2018
CompletionActual
Nov 30, 2018
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04891679
Lead sponsor
Christian Medical College and Hospital, Ludhiana, India
Responsible party
Dr. Barbie Sharma (Senior Resident, Department of obstetrics and gynecology, Christian Medical College and Hospital, Ludhiana, India) — Principal investigator
First posted
May 18, 2021
Start date
Dec 1, 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018
Last update
May 18, 2021

Study contacts

SUNITA GOYAL, MBBS, MD
study chair · Department of obstetrics and gynecology, Christian Medical College and hospital, Ludhiana

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Misoprostol

Start the discussion